Helix BioPharma Corp.
Important Dates
Helix BioPharma Corp.'s next confirmed earnings release is scheduled for November 4, 2026.
| Earnings Date | 11/4/2026 |
Share Statistics
As of April 30, 2026, Helix BioPharma Corp. has 76.38M shares outstanding.
| Shares Outstanding | 76.38M |
Financial Position
As of April 30, 2026, Helix BioPharma Corp. maintains a current ratio of 0.45, meaning it holds 0.5x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 0.45 |
| Quick Ratio | 0.45 |
| Debt / Equity | 2.44 |
Financial Efficiency
These figures cover the twelve months ended April 30, 2026.
| Employee Count | 8.00 |
Stock Price Statistics
CADAs of the close on September 23, 2026, Helix BioPharma Corp.'s stock has declined approximately 27.63% over the past 52 weeks. The 50-day moving average sits at 1.50, while the 200-day moving average is 3.51.
| 52-Week Price Change | -27.63% |
| 50-Day Moving Average | 1.50 |
| 200-Day Moving Average | 3.51 |
Balance Sheet
CADAs of April 30, 2026, Helix BioPharma Corp. holds 2.84M in cash and equivalents against 359,000.00 in total debt, resulting in a net debt position of -2.48M. Total book value stands at 14.69M, with working capital of -3.70M providing operational flexibility.
| Cash & Cash Equivalents | 2.84M |
| Total Debt | 359,000.00 |
| Net Debt | -2.48M |
| Equity (Book Value) | 14.69M |
| Book Value Per Share | 0.19 |
| Working Capital | -3.70M |
Stock Splits
Helix BioPharma Corp.'s most recent stock split took place on September 5, 2024 with a 5:1 split ratio.
| Last Split Date | 9/5/2024 |
| Split Ratio | 5:1 |